LT3419625T - Fxr agonistų panaudojimo būdai - Google Patents

Fxr agonistų panaudojimo būdai

Info

Publication number
LT3419625T
LT3419625T LTEP17709189.9T LT17709189T LT3419625T LT 3419625 T LT3419625 T LT 3419625T LT 17709189 T LT17709189 T LT 17709189T LT 3419625 T LT3419625 T LT 3419625T
Authority
LT
Lithuania
Prior art keywords
methods
fxr agonists
fxr
agonists
Prior art date
Application number
LTEP17709189.9T
Other languages
English (en)
Inventor
Bryan Laffitte
Michael BADMAN
Jin Chen
Sam LINDGREN
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3419625T publication Critical patent/LT3419625T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
LTEP17709189.9T 2016-02-22 2017-02-20 Fxr agonistų panaudojimo būdai LT3419625T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662298121P 2016-02-22 2016-02-22
US201662420661P 2016-12-12 2016-12-12
PCT/IB2017/050963 WO2017145041A1 (en) 2016-02-22 2017-02-20 Methods for using fxr agonists

Publications (1)

Publication Number Publication Date
LT3419625T true LT3419625T (lt) 2021-07-26

Family

ID=58231666

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17709189.9T LT3419625T (lt) 2016-02-22 2017-02-20 Fxr agonistų panaudojimo būdai

Country Status (24)

Country Link
US (2) US11344540B2 (lt)
EP (2) EP3848031A1 (lt)
JP (1) JP6986022B2 (lt)
KR (1) KR20180115270A (lt)
CN (2) CN108697702A (lt)
AU (1) AU2017223155B2 (lt)
BR (1) BR112018016310A2 (lt)
CA (1) CA3013186A1 (lt)
CL (1) CL2018002359A1 (lt)
CY (1) CY1124300T1 (lt)
DK (1) DK3419625T3 (lt)
ES (1) ES2878575T3 (lt)
HR (1) HRP20211032T1 (lt)
HU (1) HUE054819T2 (lt)
IL (1) IL260784B (lt)
LT (1) LT3419625T (lt)
MX (1) MX384205B (lt)
PH (1) PH12018501656A1 (lt)
PL (1) PL3419625T3 (lt)
PT (1) PT3419625T (lt)
RU (1) RU2743075C2 (lt)
SI (1) SI3419625T1 (lt)
TW (1) TWI735546B (lt)
WO (1) WO2017145041A1 (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
SI3419624T1 (sl) 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
GB201616670D0 (en) * 2016-09-30 2016-11-16 Innospec Ltd Methods, compositions and uses relating thereto
CA3039124A1 (en) 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
AR114930A1 (es) 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica
US11286252B2 (en) 2017-11-01 2022-03-29 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
US11168079B2 (en) 2017-11-01 2021-11-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
KR102731925B1 (ko) 2017-11-01 2024-11-18 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
JP7212693B2 (ja) 2017-11-01 2023-01-25 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレーターとしての架橋二環化合物
CN111278821B (zh) 2017-11-01 2023-10-03 百时美施贵宝公司 作为法尼醇x受体调节剂的螺环化合物
CN111356458A (zh) * 2017-11-30 2020-06-30 诺华股份有限公司 用于治疗肝疾病的fxr激动剂
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
JP7449300B2 (ja) 2019-02-15 2024-03-13 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとして有用な置換アミド化合物
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
US12319676B2 (en) 2019-02-15 2025-06-03 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid X receptor modulators
JP7465883B2 (ja) 2019-02-15 2024-04-11 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとしての置換二環式化合物
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CN113950329A (zh) * 2019-05-29 2022-01-18 山东青佰欣达医药科技有限公司 多羟基化胆汁酸和法尼醇x受体激动剂的联合
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
TW202122078A (zh) * 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
CN114502198A (zh) * 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
TW202308629A (zh) 2021-04-28 2023-03-01 法商Enyo製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
US20260207538A1 (en) * 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
SG11201603026PA (en) 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
HK1257648A1 (zh) * 2016-02-22 2019-10-25 Novartis Ag Fxr促效剂之使用方法
SI3419624T1 (sl) 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR

Also Published As

Publication number Publication date
AU2017223155B2 (en) 2019-08-22
CL2018002359A1 (es) 2018-12-07
US20190046519A1 (en) 2019-02-14
WO2017145041A1 (en) 2017-08-31
EP3848031A1 (en) 2021-07-14
AU2017223155A1 (en) 2018-08-09
PL3419625T3 (pl) 2021-10-25
CA3013186A1 (en) 2017-08-31
BR112018016310A2 (pt) 2018-12-26
TW201735924A (zh) 2017-10-16
PT3419625T (pt) 2021-07-07
RU2018133298A (ru) 2020-03-24
HRP20211032T1 (hr) 2021-10-01
RU2743075C2 (ru) 2021-02-15
ES2878575T3 (es) 2021-11-19
RU2018133298A3 (lt) 2020-05-27
EP3419625B1 (en) 2021-04-07
CN113679718A (zh) 2021-11-23
DK3419625T3 (da) 2021-07-12
SI3419625T1 (sl) 2021-08-31
PH12018501656A1 (en) 2019-06-03
HUE054819T2 (hu) 2021-10-28
US11344540B2 (en) 2022-05-31
MX2018010100A (es) 2018-11-09
CN108697702A (zh) 2018-10-23
HK1257647A1 (en) 2019-10-25
JP2019511478A (ja) 2019-04-25
JP6986022B2 (ja) 2021-12-22
IL260784B (en) 2022-04-01
MX384205B (es) 2025-03-14
EP3419625A1 (en) 2019-01-02
CY1124300T1 (el) 2022-07-22
KR20180115270A (ko) 2018-10-22
US20220313677A1 (en) 2022-10-06
TWI735546B (zh) 2021-08-11

Similar Documents

Publication Publication Date Title
HUE054819T2 (hu) Eljárások FXR agonista alkalmazására
IL263586B (en) Inhibitors of the menin-mll interaction
IL264758B (en) Methods for flexible resource usage
PL3507418T3 (pl) Sposoby biopochodnej derywatyzacji powierzchni celulozowych
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL254039A0 (en) Anti-pvrig antibodies and methods of use
IL251970B (en) Anti-cd79b antibodies and methods of use
DK3419624T3 (da) Fremgangsmåder til anvendelse af fxr-agonister
EP3458445A4 (en) KRAS G12C INHIBITORS
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
IL272851A (en) Methods of using dipivefrin
IL249092A0 (en) Anti-gitr antibodies and methods of use thereof
PT3548033T (pt) Compostos e respectivos métodos de utilização
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
DK3277286T3 (da) Galdesydererivater som fxr/tgr5-agonister og anvendelsesmetoder deraf
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
DK3442972T3 (da) Bromdomænehæmmere
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
PL3457851T3 (pl) Pochodne sobetiromu
DK3341379T3 (da) EZH2-hæmmere
DK3132009T3 (da) Fremgangsmåde
DK3283210T3 (da) Fremgangsmåde